DOCSLIB.ORG

Pemphigus Vulgaris Acantholysis Ameliorated by Cholinergic Agonists

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pemphigus Vulgaris Acantholysis Ameliorated by Cholinergic Agonists OBSERVATION Pemphigus Vulgaris Acantholysis Ameliorated by Cholinergic Agonists Vu Thuong Nguyen, PhD; Juan Arredondo, PhD; Alexander I. Chernyavsky, PhD; Mark R. Pittelkow, MD; Yasuo Kitajima, MD, PhD; Sergei A. Grando, MD, PhD, DSc Background: Pemphigus vulgaris (PV) is an autoim- phorylation level of E-cadherin and plakoglobin was in- mune, IgG autoantibody–mediated disease of skin and mu- creased by PV IgG, whereas this effect of PV IgG was at- cosa leading to progressive blistering and nonhealing ero- tenuated in the presence of 0.5mM carbachol. sions. Patients develop autoantibodies to adhesion Pyridostigmine bromide, an acetylcholinesterase inhibi- molecules mediating intercellular adhesion and to kerat- tor, produced effects similar to those of carbachol, which inocyte cholinergic receptors regulating cell adhesion. helps explain its clinical efficacy in a patient with active PV that was resistant to treatment with systemic gluco- Observations: To determine whether a cholinergic ago- corticosteroids. Treatment with pyridostigmine bro- nist can abolish PV IgG–induced acantholysis, litter mates mide (360 mg/d) in a patient with PV allowed to keep of neonatal athymic nude mice were injected with PV IgG his disease under control at a lower dose of prednisone together with carbachol (0.04 µg/g body weight). None than that used before starting pyridostigmine bromide of these mice developed skin lesions. Through in vitro treatment. experiments, we measured the expression of adhesion molecules in monolayers of normal human keratino- Conclusion: Elucidation of the cholinergic control of ke- cytes incubated overnight in the presence of 0.25mM car- ratinocyte adhesion merits further consideration be- bachol using semiquantitative Western blot and immu- cause of a potential for the development of novel anti- nofluorescence. Carbachol caused an elevation of the acantholytic therapies using cholinergic drugs. relative amount of E-cadherin in keratinocytes (PϽ.05) without changing that of plakoglobin (PϾ.05). The phos- Arch Dermatol. 2004;140:327-334 EMPHIGUS VULGARIS (PV) IS antholytic effects of glucocorticosteroids an autoimmune-mediated in vitro.7 We report that stimulation of the disease of skin and mucosa keratinocyte cholinergic receptors con- leading to progressive blis- trols PV IgG–induced acantholysis in neo- tering and nonhealing ero- natal mice and ameliorates the natural Psions. Therapy for patients with PV relies course of disease in a patient with PV. Cho- on the long-term use of systemic gluco- linergic agonists stimulated expression of corticosteroids in relatively large doses, E-cadherin and abolished phosphoryla- which, although lifesaving, may cause se- tion of E-cadherin and plakoglobin in ke- vere adverse effects, including death. Ac- ratinocytes caused by PV IgG. Thus, novel tive disease state is characterized by the antiacantholytic therapies may be devel- presence of serum IgG autoantibodies oped based on the antiacantholytic ef- binding to the keratinocyte cell mem- fects of cholinomimetic drugs. brane proteins. Although the antiacan- tholytic effect of glucocorticosteroids is at- METHODS tributed to immunosuppression, high doses PASSIVE TRANSFER OF PV From the Departments of of glucocorticosteroids can directly block Dermatology, University of PV IgG–induced acantholysis in vitro1,2 and Neonatal athymic nude mice were used to test California Davis, Sacramento rapidly (within 48 hours) stop blistering direct antiacantholytic effects of cholinergic ago- (Drs Nguyen, Arredondo, in patients with pemphigus without alter- nists. At the third day of life, athymic nude mice Chernyavsky, and Grando), ing the titer of autoantibodies or block- weigh approximately 1.5 g and can develop gross Mayo Clinic, Rochester, Minn skin blisters on passive transfer of PV antibod- ing antibody binding to keratinocytes (Dr Pittelkow), and Gifu 3-5 ies. This study had been approved by the Uni- University, Gifu City, Japan (“pulse therapy”). Patients develop au- versity of California Davis Review Committee (Dr Kitajima). The authors toantibodies to keratinocyte cholinergic on the Use of Animals in Research, Sacra- have no relevant financial receptors regulating cell adhesion.6 Acti- mento, Calif. We injected 52 mice intraperito- interest in this article. vation of these receptors mimics antiac- neally through a 30-gauge needle with PV (ex- (REPRINTED) ARCH DERMATOL / VOL 140, MAR 2004 WWW.ARCHDERMATOL.COM 327 ©2004 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/30/2021 periment) or normal human IgG (negative control). One subgroup PHOSPHORYLATION ASSAY of mice received PV IgG alone and the other subgroup received Quantitative phosphorylation assay was designed based on the PV IgG together with a test drug. The patients’ and control hu- 13 man IgG serum fractions were obtained using 40% ammonium established protocols, as detailed elsewhere. Briefly, cul- tured DJM-1 cells were grown to approximately 75% conflu- sulfate followed by dialysis against phosphate-buffered saline (PBS; 2 Gibco BRL, Gaithersburg, Md). The fractions were then lyophi- ence in 75-cm flasks (Corning Costar, Cambridge, Mass) in 8 serum-free keratinocyte growth medium (Clonetics Corp, San lized and reconstituted in PBS as detailed elsewhere. The nega- 2+ tive control IgG was isolated from normal human serum pur- Diego, Calif) containing 0.09mM Ca at 37°C in a humid 5% chased from Sigma Chemical Co, St Louis, Mo. carbon dioxide incubator. The cells were then treated for 14 hours with phosphate-free minimal essential medium contain- 2+ ASSESSMENT OF ACANTHOLYSIS ing 1.8mM Ca and 5% dialyzed fetal calf serum (Gibco BRL) and then treated with the same medium containing 200 µCi/mL Gross skin lesions were observed approximately 24 to 40 hours of 32P orthophosphate (Amersham Pharmacia Biotech, Inc). The after the first injection of PV IgG. Histological evaluation of le- cells were labeled for 8 hours and then exposed for 1 hour to 1 sional and perilesional skin in mice with clinical symptoms of mg/mL of pooled normal human IgG (Sigma Chemical Co) or induced PV revealed extensive intraepidermal split and nonspe- PV IgG pooled from 5 PV sera samples in the absence or pres- cific changes. To allow accurate analysis of the extent of acan- ence of 0.5mM carbachol or pyridostigmine bromide. After in- tholysis, we euthanized the mice at the preclinical stage of the cubation, the cells were lysed and the lysates were cleared by disease (ie, approximately 20 hours after the injection). The ani- centrifugation at 14000g for 10 minutes. The adhesion mol- mals were cross-sectioned at the umbilicus level and freshly fro- ecules under consideration were immunoprecipitated, re- zen. The need to compare skin specimens from the same body solved by 7.5% sodium dodecyl sulfate–polyacrylamide gel region stemmed from the fact that acantholysis in neonatal mice electrophoresis, electroblotted, and analyzed with the Phos- may vary between different anatomical regions.9 Three 6-µm thick phorImager feature of the Storm system (Molecular Dynam- cross sections of each mouse body were placed on the glass slide ics, Mountain View, Calif). To determine protein concentra- and stained with hematoxylin-eosin. The images (original mag- tion of each precipitated adhesion molecule, the samples were nification ϫ100) of 5 randomly selected longitudinal skin areas analyzed by Western blotting, as described above. The results in each specimen were photographed using a computer-linked were expressed as ratios of the radioactivity value of each ad- microscope and printed. We determined the extent of acan- hesion molecule to its protein quantity in each sample, com- tholysis in the photographs by measuring the length of the in- pared with the ratios obtained in control cultures (taken as 1.00). traepidermal split (at least 4 basal cells long) and expressed the results as percentage of the total length of epidermis in the field, STATISTICS taken as 100%. The results of quantitative experiments were expressed as IMMUNOHISTOCHEMISTRY mean±SD. Significance was determined using the t test. The results were deemed significant if the P value was less than .05. Direct and indirect immunofluorescence assays were per- formed as detailed elsewhere.8 For the direct immunofluores- cence assay, a tissue specimen was incubated for 1 hour at room REPORT OF A CASE temperature with a fluorescently labeled goat antihuman IgG an- A recently reported case of PV that had improved by ciga- tibody (Pierce, Rockford, Ill; dilution 1:200 in PBS). For the in- 14 direct immunofluorescence experiments, a tissue substrate was rette smoking and a study showing successful use of 15 first treated with a primary antibody to E-cadherin or plakoglo- nicotinamide as a steroid-sparing agent in pemphigus, bin (both from BD Transduction Laboratories, Lexington, Ky; suggested that pharmacological regulation of keratino- dilution, 1:200) and then exposed to a secondary fluorescently cyte acetylcholine (ACh) axis may be a novel antiacan- labeled antibody (Pierce). Semiquantitative indirect immuno- tholytic therapy for pemphigus because (1) cigarette fluorescence assay was performed as detailed previously,10,11 us- smoke contains the cholinomimetic agent nicotine and ing a computer-assisted image analysis with a software package (2) nicotinamide exhibits cholinomimetic effects16 ow- purchased from Scanalytics (Fairfax, Va). For each tissue speci- ing to the stimulation of ACh release17 and inhibition
Load more

Recommended publications
  • ON the VIRUS ETIOLOGY of PEMIPHIGUS and DERMATITIS HERPETIFORMIS DUHRING*, Tt A.MARCHIONINI, M.D
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector ON THE VIRUS ETIOLOGY OF PEMIPHIGUS AND DERMATITIS HERPETIFORMIS DUHRING*, tt A.MARCHIONINI, M.D. AND TH. NASEMANN, M.D. The etiology of pemphigus and dermatitis herpetiformis (Duhring) is, as Lever (33) has pointed ont in his recently published monograph (1953), still unknown, despite many clinical investigations and despite much bacteriologic and virus research using older and newer methods. There can be no doubt that the number of virus diseases has increased since modern scientific, (ultrafiltra- tion, ultracentrifuge, electron-microscope, etc.) and newer biological methods (chorionallantois-vaccination, special serological methods, tissue cultures, etc.) have been used on a larger scale in clinical research. Evidence of virus etiology, however, is not always conclusive. What is generally the basis for the assumption of the virus nature of a disease? First of all, we assume on the basis of epidemiology and clinical observations that the disease is iufectious and that we are dealing with a disease of a special character (morbus sui qeneris). Furthermore, it must be ruled out that bacteria, protozoa and other non-virus agents are responsible for the disease. This can be done by transfer tests with bacteria-free ultrafiltrates. If these are successful, final prcof of the virus etiology has to be established by isolation of the causative agent and its cultivation in a favorable host-organism through numerous transfers. Let us look now from this point of view at pemphigus and dermatitis herpetiformis (Duhring). We are not dealing here with the old controversy, whether both diseases are caused by the same virus (unitarian theory) or by two different viruses (dualistic theory) or are due to two variants of different virulence of the same virus (Duhring-virus-attenu- ated form).
    [Show full text]
  • Medicare Human Services (DHHS) Centers for Medicare & Coverage Issues Manual Medicaid Services (CMS) Transmittal 155 Date: MAY 1, 2002
    Department of Health & Medicare Human Services (DHHS) Centers for Medicare & Coverage Issues Manual Medicaid Services (CMS) Transmittal 155 Date: MAY 1, 2002 CHANGE REQUEST 2149 HEADER SECTION NUMBERS PAGES TO INSERT PAGES TO DELETE Table of Contents 2 1 45-30 - 45-31 2 2 NEW/REVISED MATERIAL--EFFECTIVE DATE: October 1, 2002 IMPLEMENTATION DATE: October 1, 2002 Section 45-31, Intravenous Immune Globulin’s (IVIg) for the Treatment of Autoimmune Mucocutaneous Blistering Diseases, is added to provide limited coverage for the use of IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid (a.k.a., Cicatricial Pemphigoid), and (5) Epidermolysis Bullosa Acquisita. Use J1563 to bill for IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid, and (5) Epidermolysis Bullosa Acquisita. This revision to the Coverage Issues Manual is a national coverage decision (NCD). The NCDs are binding on all Medicare carriers, intermediaries, peer review organizations, health maintenance organizations, competitive medical plans, and health care prepayment plans. Under 42 CFR 422.256(b), an NCD that expands coverage is also binding on a Medicare+Choice Organization. In addition, an administrative law judge may not review an NCD. (See §1869(f)(1)(A)(i) of the Social Security Act.) These instructions should be implemented within your current operating budget. DISCLAIMER: The revision date and transmittal number only apply to the redlined material. All other material was previously published in the manual and is only being reprinted. CMS-Pub.
    [Show full text]
  • Bullous Pemphigoid/Pemphigus and Administration of the Pfizer/Biontech Vaccine (Comirnaty®). Introduction the Pfizer/Bionte
    Bullous Pemphigoid/Pemphigus and administration of the Pfizer/BioNTech vaccine (Comirnaty®). Introduction The Pfizer/BioNTech vaccine (Comirnaty®) is a COVID-19-mRNA-vaccine (nucleoside modified). It is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older. [1] The nucleoside-modified messenger RNA in Comirnaty® is formulated in lipid nanoparticles, which enable delivery of the nonreplicating RNA into host cells to direct transient expression of the SARS-CoV-2 S antigen. The mRNA codes for membrane-anchored, full-length Spike glycoprotein with two point mutations within the central helix. [1] Comirnaty® has been registered in Europe since December 21st, 2020. Bullous skin diseases are a group of dermatoses characterized by blisters and bullae in the skin and mucous membranes. The most common are pemphigus and bullous pemphigoid (BP). Pemphigus and bullous pemphigoid are autoantibody-mediated blistering skin diseases. In pemphigus, keratinocytes in epidermis and mucous membranes lose cell-cell adhesion, and in pemphigoid, the basal keratinocytes lose adhesion to the basement membrane. Bullous pemphigoid is a more common disease than pemphigus [2]. Bullous pemphigoid is the most common heterogeneous subepidermal autoimmune blistering disease (incidence 7 per million person year) [3,4], with an increasing prevalence after the age of 70, although it can also occur in the younger. It is characterized by auto-antibodies against different structural proteins of the hemidesmosomes in the epidermal basement membrane zone (EBMZ). Bullous pemphigoid typically causes severe pruritus with predominantly cutaneous lesions consisting of tense (fluid filled) bullae, erythema, and urticarial plaques.
    [Show full text]
  • Rituximab Therapy in Severe Juvenile Pemphigus Vulgaris
    Rituximab Therapy in Severe Juvenile Pemphigus Vulgaris Adam J. Mamelak, MD; Mark P. Eid, BS; Bernard A. Cohen, MD; Grant J. Anhalt, MD Juvenile pemphigus vulgaris (PV) is a rare and Serum transfer and knockout mice studies gave often misdiagnosed condition. Although PV fre- evidence to both the antibody-mediated mechanism quently is severe in children, a substantial por- and target antigen in PV.2,3 Short-lived plasma cells tion of the morbidity and mortality associated that continuously are generated by specific memory with juvenile PV has been attributed to treatment. B cells or long-lived plasma cells in the bone marrow This report demonstrates the efficacy of ritux- that do not require restimulation are believed to be imab therapy in juvenile PV. We report 2 cases the source of these autoantibodies.4,5 Current PV and review the literature. Rituximab treatment treatments are designed to target either the various was effective in helping to control 2 recalcitrant cells involved in autoantibody production or the cases of juvenile PV without inducing the adverse autoantibodies themselves. effects associated with other adjuvant therapies. Rituximab, a chimeric anti-CD20 monoclonal Rituximab should be considered when treating antibody that binds and depletes B cells, has been resistant cases of PV in pediatric populations to reported to be an effective treatment in adult PV.6-13 avoid the long-term side effects of other immuno- CD20, a 33- to 37-kDa nonglycosylated trans- suppressive treatments. membrane phosphoprotein, is expressed on the Cutis. 2007;80:335-340. surface of pre–B cells, mature B cells, and many malignant B cells, but not on plasma cells or bone marrow stem cells.14 The side effects of rituximab n 1999, Bjarnason and Flosadottir1 examined the therapy are limited; thus, it may offer an effective incidence and outcomes of juvenile pemphigus and safe treatment alternative in children with PV.
    [Show full text]
  • Dermatitis Herpetiformis
    Dermatitis herpetiformis Authors: Professors Paolo Fabbri 1 and Marzia Caproni Creation date: November 2003 Update: February 2005 Scientific editor: Professor Benvenuto Giannotti 1II Clinica Dermatologica, Dipartimento di Scienze Dermatologiche, Università degli Studi di Firenze, Via degli Alfani 37, 50121, Firenze, Italy. [email protected] Summary Keywords Disease name and synonyms Definition Prevalence Clinical manifestations Differential diagnosis Etiopathogenesis Management – treatment Diagnostic criteria – methods References Summary Dermatitis herpetiformis (DH) is a subepidermal bullous disease characterized by chronic recurrence of itchy, erythematous papules, urticarial wheals and grouped vesicles that appear symmetrically on the extensor surfaces, buttocks and back. Children and young adults are mostly affected. Prevalence is estimated to be about 10 to 39 cases/100,000/year, with incidence ranging from 0,9 (Italy) to 2,6 (Northern Ireland) new cases/100,000/year. The disease is the cutaneous expression of a gluten-sensitive enteropathy identifiable with celiac disease. The clinical and histological pictures of both entities are quite similar. Granular IgA deposits at the dermo-epidermal junction, neutrophils and eosinophils together with activated CD4+ Th2 lymphocytes are supposed to represent the main immune mechanisms that co- operate in the pathogenesis of the disease. A strict gluten withdrawal from diet represents the basis for treatment. Keywords autoimmune bullous diseases, celiac disease, tissue transglutaminase, anti-endomysium antibodies, anti- tissue transglutaminase antibodies, gluten sensitivity, dapsone. deposits at the dermal papillae represent the immunological marker of the disease, that is strictly associated with a gluten-sensitive Disease name and synonyms enteropathy (GSE), indistinguishable from celiac - Dermatitis herpetiformis (DH), disease (CD). 1 - Duhring-Brocq disease, - Duhring’s dermatitis.
    [Show full text]
  • Clinical PRACTICE Blistering Mucocutaneous Diseases of the Oral Mucosa — a Review: Part 2
    Clinical PRACTICE Blistering Mucocutaneous Diseases of the Oral Mucosa — A Review: Part 2. Pemphigus Vulgaris Contact Author Mark R. Darling, MSc (Dent), MSc (Med), MChD (Oral Path); Dr.Darling Tom Daley, DDS, MSc, FRCD(C) Email: mark.darling@schulich. uwo.ca ABSTRACT Oral mucous membranes may be affected by a variety of blistering mucocutaneous diseases. In this paper, we review the clinical manifestations, typical microscopic and immunofluorescence features, pathogenesis, biological behaviour and treatment of pemphigus vulgaris. Although pemphigus vulgaris is not a common disease of the oral cavity, its potential to cause severe or life-threatening disease is such that the general dentist must have an understanding of its pathophysiology, clinical presentation and management. © J Can Dent Assoc 2006; 72(1):63–6 MeSH Key Words: mouth diseases; pemphigus/drug therapy; pemphigus/etiology This article has been peer reviewed. he most common blistering conditions captopril, phenacetin, furosemide, penicillin, of the oral and perioral soft tissues were tiopronin and sulfones such as dapsone. Oral Tbriefly reviewed in part 1 of this paper lesions are commonly seen with pemphigus (viral infections, immunopathogenic mucocu- vulgaris and paraneoplastic pemphigus.6 taneous blistering diseases, erythema multi- forme and other contact or systemic allergic Normal Desmosomes reactions).1–4 This paper (part 2) focuses on Adjacent epithelial cells share a number of the second most common chronic immuno- connections including tight junctions, gap pathogenic disease to cause chronic oral junctions and desmosomes. Desmosomes are blistering: pemphigus vulgaris. specialized structures that can be thought of as spot welds between cells. The intermediate Pemphigus keratin filaments of each cell are linked to focal Pemphigus is a group of diseases associated plaque-like electron dense thickenings on the with intraepithelial blistering.5 Pemphigus inside of the cell membrane containing pro- vulgaris (variant: pemphigus vegetans) and teins called plakoglobins and desmoplakins.
    [Show full text]
  • Exacerbation of Galli-Galli Disease Following Dialysis Treatment: a Case Report and Review of Aggravating Factors
    Open Access Case Report DOI: 10.7759/cureus.15401 Exacerbation of Galli-Galli Disease Following Dialysis Treatment: A Case Report and Review of Aggravating Factors Tejas P. Joshi 1 , Sally Shaver 2 , Jaime Tschen 3 1. Dermatology, Baylor College of Medicine, Houston, USA 2. Dermatology, Conroe Dermatology Associates, Conroe, USA 3. Dermatology, St. Joseph Dermatopathology, Houston, USA Corresponding author: Tejas P. Joshi, [email protected] Abstract Galli-Galli disease (GGD) is a rare genodermatosis that is an acantholytic variant of Dowling-Degos disease that presents as lentigo-like macules/papules with progressive reticulated hyperpigmentation. Heat, sweat, ultraviolet light exposure, and topical retinoids have been reported to exacerbate the lesions associated with GGD. Here, we present a 77-year-old woman with end-stage renal disease and GGD who reported a worsening of lesions during the summer months and following hemodialysis treatment. Despite the severity of her lesions following dialysis, she refused treatment with isotretinoin out of concern for its side effect profile. In this case report, we discuss some available treatment options for GGD and review the exacerbating factors for GGD currently reported in the literature. Categories: Dermatology Keywords: galli-galli disease, dowling-degos disease, genodermatosis, dialysis, contact dermatitis, end-stage renal disease Introduction Galli-Galli disease (GGD) is a rare, autosomal dominant genodermatosis that is an acantholytic variant of Dowling-Degos disease (DDD). DDD encompasses a spectrum of skin conditions that present with progressive reticulated hyperpigmentation; while GGD was initially postulated to be a distinct entity from DDD, more recent evidence has led to the consensus that GGD is a variant of DDD [1].
    [Show full text]
  • Histopathology of Porphyria Cutanea Tarda 133
    HISTOPATHOLOGY OF PORPHYRIA CTJTANEA TARDA*t MATJRIMAURI FELDAKER, FELDAKER, M.D., MD., HAMILTON MONTGOMERY, M.D. AND LOUIS A. BRUNSTING, M.D.MD. We wish to report the results of the histopathologic examination of the skin in 11 patients \vithwith porphyria cutanea tardatarda whowho werewere examinedexamined betweenbetween 19461946 and 1954. The microscopic findings in two patients (numbers I nndand 2) havehnve beenbeen reported previously by Brunsting and Mason (1). A preliminary report of the histopathologic findings in the first 10 patients has been given by Brunsting (2). MATERIAL Eleven patients, 10 men and one woman, with porphyria cutanea tarda were included in this study. One or more cutaneous biopsy specimens from each patient were fixed with 10 per cent formalin and stained with hematoxylin and eosin,eosiu, various elastic-tissue stains such as elastin H (Grubler), and an modified aldehyde-fuchsin stain (3)t whichwhich wewe preferprefer toto thethe elastinelastin HH oror WeigertWeigert stain, stain van Gieson stain forfor collagen,collagen, periodicperiodic acid acid Schiff Schiff stain stain (P.A.S., (PAS., that is, Hotch- kiss-McManus stain) for polysaccharides with and without pretreatment with diastase, mucin stains such as mucin D (4) counterstained with 2 per cent indigo carmine, Mallory's potassium ferrocyanide stain for the demonstration of hemo- siderin, and silver nitrate stain counterstained with\vith hematoxylin to demonstrate melanin. Stains for amyloid, Maresch-Bielschowsky stain for reticulum fibers (Gitterfasern) arid the Giemsa stain to demonstrate mast cells were done on all specimens. Biopsy was performed on the dorsum of the hand or finger iiiin about 50 per cent of the patients and, with one exception, all specimens were removed from thethe usuallyusually exposed areas of the body.
    [Show full text]
  • D-Penicillamine-Induced Pemphigus Vulgaris in a Patient with Scleroderma-Rheumatoid Arthritis Overlap Syndrome
    318 Letters to the Editor D-Penicillamine-induced Pemphigus Vulgaris in a Patient with Scleroderma-Rheumatoid Arthritis Overlap Syndrome Andrea Szegedi1,Pe´ter Sura´nyi2, Gabriella Szu¨cs3,Ma´ria Kiss4,Ja´nos Hunyadi1 and Ja´nos Gaa´l2* 1Department of Dermatology, Medical and Health Science Center, University of Debrecen, 2Department of Rheumatology, Kene´zy Gyula Hospital, Barto´k B. str. 2-26, HU-4043 Debrecen, 33rd Department of Internal Medicine Medical and Health Science Center, University of Debrecen, Debrecen and 4Department of Dermatology, University of Szeged, Szeged, Hungary. *E-mail: [email protected] Accepted January 9, 2004. Sir, pain decreased, the skin softened, and her general health Pemphigus vulgaris (PV) developing in conjunction status and movement capabilities improved significantly. Ten with D-penicillamine treatment is a rare disorder; to days after the initiation of higher dose D-penicillamine, erosions and ulcers developed on the inner surface of the lips date the number of described cases is about 100 (1). (Fig. 1). Mouth balm was applied. Most reports of D-penicillamine-induced PV are in At the end of February she again reported to the patients with rheumatoid arthritis (RA) (2), but there dermatology unit with enlarged and painful lip ulcers and are no data in the medical literature about this com- blisters that appeared throughout the body. Nicolsky’s sign plication in systemic sclerosis-rheumatoid arthritis was positive, the histological examination showed perivascular SSc-RA overlap syndrome. We here report a case of lymphocytic infiltration, oedema and incipient acantholysis. D-penicillamine-induced PV in a patient with SSc-RA Direct immunofluorescence demonstrated IgG and C3 staining overlap syndrome.
    [Show full text]
  • Download Article
    SKINTEST Skin Test Christina P. Linton 1. Which fungal strain is the most common cause 6. Which of the following conditions is characterized of tinea capitis in the United Kingdom and by intraepidermal blistering? North America? a. Bullous pemphigoid a. Trichophyton tonsurans b. Porphyria cutanea tarda b. Microsporum audouinii c. Herpesvirus infection c. Trichophyton rubrum d. Dermatitis herpetiformis d. Microsporum canis 7. What is the mechanism of action of injectable local 2. What percentage of cells in the epidermis are anesthetics? keratinocytes? a. Blockage of potassium channels a. 50% b. Inhibition of cyclooxygenase b. 65% c. Blockage of sodium channels c. 80% d. Inhibition of prostaglandins d. 95% 8. Which of the following statements most accurately 3. Which of the following conditions is inherited in describes pemphigus vulgaris? X-linked fashion? a. Onset is most common in the third and fourth a. Tuberous sclerosis decades of life. b. Incontinenta pigmenti b. Initial lesions generally occur on the trunk. c. Ataxia telangiectasia c. Auspitz sign is usually positive. d. Neurofibromatosis d. Untreated disease is commonly fatal. 4. What does the Greek root of the term ‘‘ichthyosis’’ 9. What does the term ‘‘acantholysis’’ refer to on a mean? dermatopathology report? a. Fish a. Loss of intercellular connections b. Crocodile b. Reduced thickness of the granular layer c. Elephant c. Abnormal retention of keratinocyte nuclei d. Lizard d. Intercellular edema 5. Lichen striatus most commonly occurs in which 10. Approximately what percentage of untreated anatomic location? syphilis cases progressed to tertiary syphilis? a. Face a. 15% b. Chest b. 33% c. Abdomen c.
    [Show full text]
  • Transcription
    Amethyst: Welcome, everyone! This call is now being recorded. I would like to thank you for ​ being on the call this evening and to our Sponsors Genentech, Principia Biopharma, Argenx, and Cabaletta Bio for making today’s call possible. Today’s topic is Peer Support to answer your question about living with pemphigus and pemphigoid with the IPPF’s Peer Health Coaches. So before we begin, I want to take a quick poll to see how many of you have connected with an IPPF Peer Health Coach (either by phone or email)? While you are answering the poll let me introduce you to the IPPF Peer Health coaches: Marc Yale is the Executive Director of the IPPF and also works as a PHC. Marc was diagnosed ​ in 2007 with Cicatricial Pemphigoid, a rare autoimmune blistering skin disease. Like others with a rare disease, he experienced delays in diagnosis and difficulty finding a knowledgeable physician. Eventually, Marc lost his vision from the disease. This inspired him to help others with the disease. In 2008, he joined the IPPF as a Peer Health Coach. Becky Strong is the Outreach Director of the International Pemphigus & Pemphigoid ​ Foundation and also works as a PHC. She was diagnosed with pemphigus vulgaris in 2010 after a 17-month journey that included seeing six different doctors from various specialties. She continues to use this experience to shine a light on the average pemphigus and pemphigoid patient experience of delayed diagnosis and bring attention to how healthcare professionals can change the patient experience. Mei Ling Moore was diagnosed with Pemphigus Vulgaris in February of 2002.
    [Show full text]
  • Oral Signs of Systemic Disease CDA 2015 Lecture Notes
    2015-08-28 Oral Signs of Oral Signs of Systemic Disease Systemic Disease Why do you need to know? ! AHA! I diagnosed your systemic disease – less likely ! Helping your patients with known Karen Burgess, DDS, MSc, FRCDC systemic diseases - more likely Oral Pathology and Oral Medicine, Faculty of Dentistry, University of Toronto Department of Dentistry, Princess Margaret Hospital Department of Dentistry, Mt Sinai Hospital 2015-08-29 2015-08-29 2015-08-29 2015-08-29 2015-08-29 2015-08-29 Normal or Abnormal? Clinical description ! Type of abnormality (shape) ! The hardest part of oral pathology ! Number ! Colour ! Consistency ! Size - measure accurately ! Surface texture ! Location 2015-08-29 2015-08-29 2015-08-29 1 2015-08-28 Vocabulary Clinical description ! Ulcer ! Type of abnormality (shape) ! Vesicle/Bulla ! Number ! Macule ! Colour ! Patch ! Consistency ! Plaque ! Size - measure accurately ! Polyp- sessile or pedunculated ! Surface texture ! Location 2015-08-29 2015-08-29 2015-08-29 Description 2015-08-29 2015-08-29 2015-08-29 Differential Diagnosis Differential Diagnosis Differential Diagnosis ! Erythema multiforme ! Mucous membrane pemphigoid ! Primary herpes ! Erythema multiforme –"Any genital or eye lesions –"How long has it been present? ! Mucous membrane pemphigoid –"Any blisters? –"Any skin lesions? ! Pemphigus vulgaris ! Pemphigus vulgaris –"any skin lesions? ! Lichen planus ! Primary herpes –"Any blisters? –"How long has it been present? ! Lichen planus What information will help you narrow down –"Any other symptoms – malaise,
    [Show full text]